Why the Bears Are Wrong About Keryx Biopharmaceuticals Stock
I haven't exactly been a bull when it comes to Keryx Biopharmaceuticals (NASDAQ: KERX). For starters, it's not even a biotech company (trying for the old "bait-and-switch" move, eh?). It doesn't own a drug pipeline. Worst of all, stubbornly slow sales of its only drug, Auryxia, have provided all the warning I need to stay away from the stock.
But things may be about to change.
No, I'm still not interested in adding it to my portfolio, but Auryxia is showing signs of life. Management thinks it can even bring in a nice bounty in 2017, and an upcoming decision from the U.S. Food and Drug Administration -- likely the reason for a bump in the share price recently -- could greatly expand its potential market.
Source: Fool.com
